Results of pregnancy termination for foetal congenital or chromosomal disorders or intrauterine foetal death by oral mifepristone and/or intravasinal misoprostol; results of a retrospective study;Uitkomsten van zwangerschapsafbreking wegens foetale congenitale of chromosomale afwijkingen en bij intra-uteriene vruchtdood door middel van mifepriston oraal en/of misoprostol vaginaal; resultaten van een retrospectieve studie

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 14, 2007, Pages 815-820

  Verhulsdonk, M T P G ^a   Papatsonis, D N M ^a   Heydanus, R ^a  

^a AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; MISOPROSTOL; PETHIDINE;

ADULT; ANALGESIA; ARTICLE; BLEEDING; CHROMOSOME DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; EPIDURAL ANESTHESIA; FEMALE; FETUS DEATH; FETUS DISEASE; FEVER; GESTATIONAL AGE; HUMAN; LABOR INDUCTION; MAJOR CLINICAL STUDY; MEDICAL RECORD; NAUSEA; NETHERLANDS; OUTCOME ASSESSMENT; PLACENTAL DELIVERY; PREGNANCY TERMINATION; PREMATURE FETUS MEMBRANE RUPTURE; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; SURGICAL RISK; SURGICAL TECHNIQUE; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; UTERUS RUPTURE; VOMITING;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADULT; FEMALE; FETAL DEATH; FETAL DISEASES; HUMANS; MIFEPRISTONE; MISOPROSTOL; PARITY; PREGNANCY; PREGNANCY TRIMESTER, SECOND; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34248136844     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Weiner CP. Fetal death. In: James DK, Steer PJ, Weiner CP, Gonik B, editors. High risk pregnancy management options. Philadelphia: Elsevier; 2006. p. 574-9.
2. French L. Oral prostaglandin E2 for induction of labour [Cochrane review]. Cochrane Database Syst Rev. 2001;(2):CD003098.
3. Kelly AJ, Kavanagh J, Thomas J. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term [Cochrane review]. Cochrane Database Syst Rev. 2001;(2):CD003101.
4. Hutton E, Mozurkewich E. Extra-amniotic prostaglandin for induction of labour [Cochrane review]. Cochrane Database Syst Rev. 2001; (2):CD003092.
5. Luckas M, Bricker L. Intravenous prostaglandin for induction of labour [Cochrane review]. Cochrane Database Syst Rev. 2000;(4): CD002864.
6. Boulvain M, Kelly A, Lohse C, Stan C, Irion O. Mechanical methods for induction of labour [Cochrane review]. Cochrane Database Syst Rev. 2001;(4):CD001233.
7. Kanhai HH, Keirse MJ. Induction of labour after fetal death: a randomized controlled trial of two prostaglandin regimens. Br J Obstet Gynaecol. 1989;96:1400-4.
8. Kanhai HH, Keirse MJ. Low-dose sulprostone for pregnancy termination in cases of fetal abnormality. Prenat Diagn. 1993;13:117-21.
9. Bugalho A, Bique C, Machungo F, Faaundes A. Induction of labor with intravaginal misoprostol in intrauterine fetal death. Am J Obstet Gynecol. 1994;171:538-41.
10. Feenstra J, Borst F, Huige MC, Oei SG, Stricker BHCh. Acuut myocardinfarct na toediening van sulproston. Ned Tijdschr Geneeskd. 1998;142:192-5.
11. Boer MA de, Gemund N van, Scherjon SA, Kanhai HH. Low dose sulprostone for termination of second and third trimester pregnancies. Eur J Obstet Gynecol Reprod Biol. 2001;99:244-8.
12. Stoutjesdijk JA, Alsma I, Wildschut HIJ. Zwangerschapsafbreking in het tweede trimester met dinoproston vaginaal gevolgd doot sulproston intraveneus, op de indicatie 'foetale congenitale afwijkingen'; resultaten van een retrospectieve studie. Ned Tijdschr Geneeskd. 2004;148:1293-6.
13. Hendricks CH, Brenner WE, Ekbladh L, Brotanek V, Fishburne jr JI. Efficacy and tolerance of intravenous prostaglandins F 2 and E 2. Am I Obstet Gynecol. 1971;111:564-79.
14. Jain JK, Kuo J, Mishell jr DR. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet Gynecol. 1999;93:571-5.
15. Merrell DA, Koch MA. Induction of labour with intravaginal misoprostol in the second and third trimesters of pregnancy. S Afr Med J. 1995;85(10 Suppl):1088-90.
16. Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol. 2002;186:470-4.
17. Ashok PW, Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. Br J Obstet Gynaecol. 1999;106:706-10.
18. Jain JK, Mishell jr DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med. 1994;331:290-3.
19. Hale RW, Zinberg S. Use of misoprostol in pregnancy. N Engl J Med. 2001;344:59-60.
20. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88-92.
21. Danielsson KG, Marions L, Rodriguez A, Spur BW, Wong PY, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol. 1999;93: 275-80.
22. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344:38-47.
23. Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG. 2002;109:1290-4.
24. Heus R de, Graziosi GC, Christiaens GC, Bruinse HW, Mol BW. Medical management for termination of second and third trimester pregnancies: a comparison of strategies. Eur J Obstet Gynecol Reprod Biol. 2004;116:16-21.
25. Ngai SW, Tang OS, Ho PC. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Pract Res Clin Obstet Gynaecol. 2003;17:765-75.
26. Thong KJ, Lynch P, Baird DT. A randomised study of two doses of gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Contraception. 1996;54: 97-100.
27. Herabutya Y, Chanrachakul B, Punyavachira P. Second trimester pregnancy termination: a comparison of 600 and 800 micrograms of intravaginal misoprostol. J Obstet Gynaecol Res. 2001;27:125-8.